© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Diatrizoic acid turned the tide for diagnostic imaging almost eight decades ago. Before its arrival, physicians leaned on rudimentary options for visualizing soft tissue, getting little help detecting hidden pathologies. In the 1950s, scientists started with triiodinated benzoic acids, chasing reliable x-ray contrast with low toxicity. Diatrizoic acid found its way to the front of this race, soon outperforming its older cousins because of its strong radiopacity and solubility profile. Progress wasn’t just a matter of smarter chemistry—it came from watching patients’ reactions and narrowing down the safest, most effective formula for everyday use. Hospitals worldwide embraced it, and by the late 20th century, it became a go-to for procedures like urography, angiography, and gastrointestinal imaging. While newer non-ionic agents have since stepped into the spotlight, diatrizoic acid still occupies a crucial spot in the toolkits of many radiology departments, offering a blend of performance and value.
Most medical staff recognize diatrizoic acid by its sodium and meglumine salt forms. These salts are the ingredients behind classic brands such as Hypaque, Urografin, and Renografin. Diatrizoic acid’s molecules pack three iodine atoms each. This isn’t just a trivial fact—it’s the reason x-rays can’t slip past, highlighting soft tissues that bones once overshadowed in plain film studies. Diatrizoic acid shows up in both injectable and oral formulations. Vials often range between 50 to 100 milliliters for intravenous use, and oral forms help spotlight the gastrointestinal tract during fluoroscopic exams. Beyond bottles and syringes, its role extends to specialized products for use in vet clinics, research imaging, and even as a calibration tool in laboratory radiological testing.
Diatrizoic acid stands as a white to off-white crystalline powder, usually odorless. It dissolves fairly well in water—a must for any intravenous or oral contrast agent—yielding a clear, colorless solution when reconstituted for medical use. With a molecular weight over 600 g/mol, it brings three iodine atoms into each molecule, packing a heavy punch for x-ray absorption. Its density, melting point near 250°C (decomposition), and high osmolarity in salt solutions drive both powerful contrast effects and the need for careful handling to avoid side effects. The pH for injectable preparations sits around 6.6 to 7.6, keeping its solutions both shelf-stable and safe for vascular administration. These characteristics set the boundaries for how it behaves in the body, how it is handled on the back table, and what precautions medical teams take during use.
Pharmaceutical-grade diatrizoic acid products come with precise details: iodine content (usually around 46% by weight), sodium or meglumine salt concentration, solution osmolarity, and viscosity at 37°C. Product inserts list batch-specific sterility data, pyrogen limits, particulate matter checks, and shelf-life, usually capped between 24 and 36 months with drugs stored at controlled room temperature. Labels highlight contraindications, known drug interactions, and allergy risk warnings—especially for patients with previous iodine sensitivity. Safety seals, tamper-evident packaging, and lot tracking maintain regulatory confidence in every step from factory to pharmacy shelf. This isn’t just about compliance—these details guide health workers in safe and effective use.
Synthesis of diatrizoic acid follows the principles laid down by early researchers. The process begins with the triiodination of benzoic acid, using iodine monochloride or similar reagents, yielding a 2,4,6-triiodobenzoic acid backbone. Carboxylation and subsequent purification steps help separate the compound from unreacted precursors and byproducts. Crystallization and drying finish the process, producing stable, pure diatrizoic acid. Converting it into injectable forms involves neutralizing with sodium hydroxide or mixing with meglumine under aseptic conditions, dissolving the resulting salt in sterile water, and filtering to remove particulates. Manufacturers subject every kilogram to pharmaceutical analytics—HPLC, NMR, and iodine titration, just for starters—to guarantee purity, potency, and absence of harmful impurities.
Diatrizoic acid’s chemistry revolves around its carboxyl group and the trio of iodine atoms hugging the aromatic ring. The acid group allows salt formation with metals and amines, such as in sodium diatrizoate and meglumine diatrizoate, which alters solubility and pharmacokinetic profiles. Derivatization reactions often focus on modifying the ring structure to lower toxicity or modify excretion routes. Some research labs have grafted polar groups onto the acid to cut down on osmolality, but these derivatives tend to trade off cost or other properties. Incompatibilities can crop up—mixing in non-approved additives or using diatrizoic acid with certain chemotherapeutics can trigger unanticipated precipitation or degrade performance.
Diatrizoic acid sometimes travels under different flags. Its sodium salt goes by Diatrizoate Sodium, Urografin, and Hypaque. The meglumine salt version turns up as Renografin, Gastrografin, or Angiografin in various markets. You might see chemical shorthand like 3,5-bis(acetamido)-2,4,6-triiodobenzoic acid on technical sheets. Across pharmacopoeias, these synonyms can complicate procurement and licensing, but the core remains the same: three iodines, one benzoic acid core, and a precise safety profile that has held steady through decades of clinical practice.
Handling diatrizoic acid safely takes more than reading a label. Healthcare workers coat hands in gloves, use luer-lock syringes to prevent leaks, and check every batch’s sterility before use. Pre-administration protocols call for allergy screening: patients with past iodine or shellfish reactions, severe asthma, or compromised kidney function get extra scrutiny. Emergency crash carts must sit nearby, loaded with antihistamines and steroids in case of anaphylactoid reactions. Medical teams keep an eye out for extravasation, especially with high-osmolar injections, watching for swelling, pain, or skin reactions at the IV site. Waste handling follows hazardous pharmaceutical protocols—the high iodine content means any spills or expired batches go in dedicated containers, not regular landfill waste. Technicians and nurses log lot numbers after every dosage, tying each administration to a clear paper trail in case of adverse event tracking.
Hospitals rely on diatrizoic acid as a backbone for contrast-based x-ray and CT studies. Gastrointestinal departments use it for oral and rectal imaging, especially in barium-allergic patients or suspected perforations. Radiology corridors see diatrizoic-based agents injected for blood vessel visualization during angiography and cardiac catheterization. Urology follows its trail through kidneys and bladders in IV pyelograms, catching stones, tumors, or congenital malformations in crisp outline. Some surgeons reach for diatrizoic acid in post-operative leak testing: its high radiopacity quickly picks out trouble spots that plain water, saline, or air can’t reveal. In the research world, the compound stands in as a radiological marker or calibration standard, especially in preclinical imaging platforms where live animal toxicity profiles matter. Even veterinary clinics sometimes put it to work, highlighting blockages or tumors in pets and livestock.
The story of diatrizoic acid continues to unfold in research labs. Clinical trials track patient outcomes with high-osmolar versus low-osmolar contrast agents, measuring not just efficacy but also cost-effectiveness in tough economic settings. Analytical chemists work on faster, greener synthesis methods, reducing hazardous waste in line with global environmental targets. A steady flow of bench studies investigates new derivatives, aiming to cut toxicity and extend imaging times for complex studies. Researchers keep testing diatrizoic acid’s boundaries—looking at its role in combination imaging, where the chase for multi-modal agents remains fierce. Diagnostic imaging techs still run comparative studies, weighing the benefits of diatrizoic acid against newer agents, especially in regions that balance budget limits with growing demand for precision imaging.
Medical journals have built a formidable library on diatrizoic acid’s safety record. Clinicians recorded early on that its high osmolarity led to vein irritation, pain at injection sites, and rare cases of nephrotoxicity, especially in patients with compromised renal function. Adverse reactions tend to run from mild—nausea, flushing, urticaria—to the life-threatening, with anaphylactoid shock, convulsions, or severe cardiac arrhythmias rarely but critically reported. Researchers discovered the value of rigorous pre-screening and slower injection rates for high-risk patients, as well as replacing high-osmolar salts with lower-osmolar alternatives where possible. Prospective trials show modern resuscitation protocols, better patient monitoring, and improved standard operating procedures bring down mortality and serious morbidity rates. Toxicological studies on long-term exposure indicate quick renal clearance in healthy subjects, but call for caution in the elderly and those with kidney or thyroid disorders. Dosage management, hydration protocols, and emergency response training form the core of toxicity reduction strategies, keeping the focus on patient safety while using a time-tested agent.
The road ahead for diatrizoic acid looks both challenging and full of potential. While newer, non-ionic contrast agents continue to grab market share in developed countries, the affordability and proven track record of diatrizoic-based products keep them firmly planted in many health systems. Research efforts aim to bring down osmolarity and minimize side effects, with interest in co-formulating with protective agents to limit renal toxicity and allergic reactions. Eco-friendly production methods top industry wish lists, moving toward sustainable, waste-reduced synthesis cycles. Digital health and AI-driven imaging platforms may yet breathe new life into established contrast agents like diatrizoic acid, as data-driven protocols optimize dose, timing, and risk prediction for every patient. With millions worldwide needing reliable imaging each year, diatrizoic acid’s practical blend of availability, safety knowledge, and technical adaptability means it will keep finding work on the front lines of medical diagnostics for years to come.
Most folks don’t think twice about what makes medical scans work, but diatrizoic acid plays a key role behind the scenes. This compound, known by some as a contrast agent, helps turn blurry medical images into clear roadmaps. Hospitals rely on it for procedures like X-rays, CT scans, and angiography. When someone needs a closer look at blood vessels or the intestines, doctors often use diatrizoic acid to highlight those tissues. After a simple injection or an oral dose, x-rays show more than just grey smudges—they reveal blockages, tumors, or injuries that might otherwise stay hidden.
I’ve seen firsthand how stressful any waiting game with health can feel. A friend struggled with stomach pains for weeks, bounced between clinics without real answers. The breakthrough only came after a scan with diatrizoic acid. The doctors finally spotted the problem: a growth hiding in plain sight. Being able to see inside the body with such clarity changed the outcome for him and his family. Early detection saves lives, and diatrizoic acid helps doctors make that happen before things get worse.
Any chemical in the blood sparks worry. Diatrizoic acid comes with its set of risks, and allergic reactions can spring up quickly. Research points out that most people handle this contrast agent just fine, but some patients face higher odds of trouble. Folks with kidney trouble, a history of allergies, or thyroid disease need extra attention. Medical teams have learned to spot allergy signs and move fast with treatment. Drinking plenty of water after the scan helps flush the chemical out, lowering the chance of kidney strain. Hospitals across the world use strict screening protocols and monitor patients during and after imaging.
Health care keeps evolving, with researchers hunting for new solutions every year. Some newer contrast agents have entered clinics, offering fewer side effects for people prone to allergies or kidney issues. For some scans, doctors try options like gadolinium for MRIs. Not every patient can use diatrizoic acid safely, so these alternatives open up doors. The goal always stays the same: make each scan as safe as possible without losing accuracy.
Patients should always know what’s being put in their bodies. Honest conversations between doctors and patients matter more than any test result. Before agreeing to a scan, folks deserve to hear why a contrast agent like diatrizoic acid makes sense in their case and what side effects to watch for. Asking questions and sharing concerns can make a world of difference.
Medical imaging relies on contrast agents, and diatrizoic acid stands as a reliable choice in many hospitals. Years of research and clinical experience have shaped how it’s used today. As science moves forward and patient voices grow louder, expect even safer options on the horizon—because everyone deserves clear answers when it comes to their health.
Diatrizoic acid finds a place on the shelves of hospitals and imaging centers, mainly as a contrast agent. Many folks have never heard of it until the doctor schedules a scan and the nurse rolls in a bottle ready for injection. The story often ends with crisp X-ray images, but sometimes a patient learns about this chemical in a less friendly way—through side effects.
A lot of people report a metallic taste in the mouth or a rush of warmth moving through their body. Sometimes, a wave of nausea follows right behind the injection. On busy radiology floors, it’s something nurses mention as they set up an IV. For those who live with sensitive stomachs or anxiety, even mild effects may turn a routine scan into a nerve-wracking ordeal.
Some patients face hives, itching, or even swelling in their throat and face—and this can escalate fast. Allergic reactions to diatrizoic acid don’t show up for most, but in those rare seconds when someone starts gasping and the team races for epinephrine, the importance of asking about allergies or prior reactions becomes painfully clear.
Contrast-induced nephropathy isn’t a term most patients toss around. Yet, kidney injury from diatrizoic acid can knock people off their feet, especially those already living with diabetes or heart disease. The conversation around these scans can’t skip over kidney health. Regular hydration before and after the procedure can help lower risk, and doctors usually check kidney function with blood work beforehand. It’s not overkill—it’s prevention working at the bedside.
Some people walk out of the scan feeling lightheaded, maybe noticing their heart racing. Diatrizoic acid can sometimes cause irregular heart rhythms or sudden drops in blood pressure. The numbers favor the patient—heart problems aren’t the rule—but data from hospital records show these risks need attention, especially in older adults or those carrying complex health histories.
Medication lists grow longer as we age. Combining diatrizoic acid with certain drugs, like those for high blood pressure or diabetes, can set off a cascade of effects. Metformin users, for example, risk lactic acidosis if kidneys falter right after a scan. A pharmacist’s quick review or a careful pause in medication can prevent days or even weeks of recovery from an easily avoidable complication.
Panic, fear, or confusion doesn’t always come from the scan itself. The temporary effects of diatrizoic acid—headaches or dizziness—sometimes play tricks on a person’s sense of control or calm. Particularly for those with anxiety disorders, the experience can linger long after images get uploaded to the doctor’s screen.
Education acts as the best early defense. Medical teams can check medical histories carefully and stay alert during scans. Having emergency medicine close at hand makes a difference, but ongoing research into safer, lower-risk contrast agents offers hope for everyone—especially the medically vulnerable. Patients benefit from honest conversations about risks, steps to limit them, and alert care every step of the way.
Hospitals and clinics keep diatrizoic acid stocked for one practical reason: visibility. It’s a contrast agent, injected or swallowed so that doctors can see inside bodies with X-rays or CT scans. There’s no trick to it — this chemical solution outlines organs and blood vessels better than nature manages on its own.
I remember the chilled hush of a radiology wing, nurses prepping trays and patients shifting in plastic chairs. There, diatrizoic acid moved from its brown glass vial to the center of attention, sometimes met by worried glances from folks who had never heard the name. Most of the time, doctors or technicians explained what would happen in a few, simple sentences. The focus always stayed on helping the patient feel comfortable despite the clinical flavor of the entire process.
The route depends on what the doctor needs to see. Diatrizoic acid can be swallowed as a liquid, or sent through a nasogastric tube for gut investigations. For looking at blood vessels or the urinary tract, it travels through a thin needle straight into a vein — what the medical world calls intravenous injection. Sometimes, the team uses a catheter and delivers the solution right where imaging needs a boost, like into the bladder or the spinal canal. You won’t find anyone suggesting one-size-fits-all dosing. Each patient gets the volume that fits the scan and body weight. Measuring and mixing happens with care — real attention to concentration and cleanliness — because mistakes risk side effects or complications.
Many patients land in the imaging suite with nagging questions about pain, bleeding, or changes that don’t add up. A clear scan, sharpened by diatrizoic acid, narrows those questions. My experience showed me that families often wait on these results, hoping for clarity or relief. Doctors want to avoid false negatives — missing a blockage, planning a surgery without accurate maps, or skipping steps in diagnosis because the “picture” isn’t clear.
On top of that, allergic reactions stay top of mind for everyone in healthcare. The acid's iodine content sometimes sparks hives or trouble breathing. Staff pre-screen patients for allergies and keep emergency gear close. Once, I watched a team handle a mild reaction, calmly and quickly — monitoring, pausing the procedure, helping the patient recover. Such moments underline the importance of thorough preparation and communication.
Relying on diatrizoic acid shines a light on areas where medical care can improve. Not everyone knows what’s in their contrast solutions. Clear, jargon-free explanations smooth out consent conversations. Regular staff training lowers risk, not just for allergic reactions but for kidney complications in patients with pre-existing conditions. In the real world, patients trust their lives to a process with little room for shortcuts. Good record-keeping, informed choices, and double-checking each step all help build that trust.
Plenty of research goes into finding safer alternatives and personalizing how contrast agents get delivered. Patients want the best images with the fewest risks. As more clinics invest in training and open conversations, less gets left to chance. Diatrizoic acid rarely gets the spotlight, but its journey from vial to vein tells a bigger story: every detail in medicine counts, especially when stakes run high for patients and their families.
Medical teams often turn to Diatrizoic acid—sometimes labeled as amidotrizoic acid—whenever a high-quality contrast agent makes a difference in procedures like CT scans and angiography. This substance helps doctors get a clearer picture inside the body, but using it brings a few red flags that can't be ignored.
Anyone who’s had serious reactions to iodine-containing contrast agents before sits high on the contraindication list. Even with advances in premedication and protocols, the risk of triggering a reaction looms large. According to studies in radiology, patients with a past history of reactions face higher odds of everything from hives to anaphylaxis. Having worked around emergency rooms during radiology consults, I’ve seen just how fast reactions can escalate. If there’s been any allergic episode before, using Diatrizoic acid doesn’t make sense unless no safer options exist.
The kidneys clear Diatrizoic acid from the body. People with kidney damage or chronic kidney disease throw up another big warning sign. If the kidneys can’t flush the agent, it can build up, harming the kidneys even further or pushing someone into acute renal failure. Research published by the American Society of Nephrology points to contrast-induced nephropathy as a real concern. In the clinics I’ve worked in, this issue crops up most in elderly patients or those with diabetes. Screening kidney function ahead of time often saves people from serious trouble.
Diatrizoic acid contains iodine, which can crank up thyroid hormone production. For people with untreated or unstable hyperthyroidism, that extra load of iodine sometimes sparks a thyroid storm—a dangerous, sometimes fatal surge in metabolism. Many clinicians check thyroid profiles as part of routine pre-scan workups for this reason. I remember treating a patient whose heart rate skyrocketed following an IV contrast injection. After that case, I paid a lot more attention to thyroid history in patient charts.
Injecting Diatrizoic acid raises the volume the heart manages, which adds stress to a failing heart. If someone has decompensated heart failure or unstable angina, even a standard dose can destabilize them. Cardiac compromise can also mean more trouble if a reaction occurs. I’ve seen rapid decline in cardiac patients who received contrast agents without enough precaution. Sticking to the lowest effective dose and ensuring cardiac monitoring can lower risk here.
Patients who have multiple myeloma—a blood cancer—sometimes develop thick blood or kidney blockages when given certain contrast agents. Add in dehydration, and the chance of kidney shutdown grows. Recommendations from hematologists stress proper hydration before, during, and after imaging if scanning can’t be avoided. In outpatient clinics, fluids and close observation help protect these vulnerable people.
Counteracting risk starts with thorough patient history. Pre-scan kidney checks, allergy screening, and careful review of medications and coexisting illnesses head off the lion’s share of disasters. For high-risk groups, alternatives like non-iodinated contrast or MRI scans might sidestep the danger. Education for both clinicians and patients goes a long way; everyone benefits when more eyes catch potential contraindications before reaching the imaging suite.
Pregnancy and breastfeeding throw a spotlight on every health decision, leading to a tough balancing act between the mother’s needs and the baby’s safety. Diatrizoic acid, found in contrast agents for x-rays and some CT scans, sits squarely in this debate. Many parents-to-be hear about it in a hospital room, just before a doctor orders a diagnostic scan. There’s nothing abstract about the concern: will a single test harm their developing child or affect milk?
Experience with this drug stretches back decades, yet clear data on how it affects a pregnant or nursing mother—and her child—remains frustratingly thin. Research points to a crucial fact: diatrizoic acid passes through the placenta. Animal studies have found evidence of harm at doses much higher than humans typically get for imaging. It’s not about fear-mongering, but it’s important not to sugarcoat things: drug labels, including those reviewed by the FDA, consistently warn about fetal risk.
For breastfeeding mothers, the story plays out in a similar way. Small amounts of diatrizoic acid end up in breast milk after a scan, but the actual dose passed along to the infant looks tiny. Experts at organizations like the American College of Radiology have said there is no need to interrupt breastfeeding after most radiological contrast exposures, including diatrizoic acid, given the low absorption in the baby’s gut. Moms sitting in the imaging waiting room often want certainty, but what’s out there is cautious reassurance, not a guarantee.
Doctors rarely lean on this contrast agent just for routine checks during pregnancy. Its use pops up when better answers are critical for a mother’s care—for example, discovering a bowel blockage or checking for a complicated infection. The message from years in clinical medicine rings clear: necessity trumps caution if skipping the scan puts two lives at risk. But it matters that care teams treat each case individually, giving families clear facts so they can take part in the decision. I’ve seen people weigh options with their providers, often choosing less risky methods when possible, like ultrasound or MRI without contrast.
Improving safety for pregnant and breastfeeding mothers starts with good habits: only using diatrizoic acid if there’s a strong reason, exploring safer alternatives, and balancing the risks with the possible benefits. Imaging techniques like low-dose CT, MRI, and ultrasound have pushed many doctors to reserve diatrizoic acid for truly urgent cases. This approach calls for constant education in both hospitals and primary care—from the radiologist, who knows the risks inside-out, to the family doctor seeing worried parents in the office.
Pushing for open conversations about any exposure during these crucial months gives patients power. Families deserve to understand the numbers, not just plain reassurances. Researchers can also do better by filling the gaps in our knowledge—tracking outcomes for children and mothers over time, and updating guidelines as new data arrives.
Diatrizoic acid presents a classic example of weighing benefits against real, though sometimes small, risks. The comfort should come from open communication and informed choices—never making someone feel like a bystander in their own care. With better evidence and honest dialogue, medical teams and families create safer journeys through pregnancy and nursing. In my view, good medicine always starts with that trust.
| Names | |
| Preferred IUPAC name | 3,5-bis(acetamido)-2,4,6-triiodobenzoic acid |
| Other names |
Amidotrizoic acid Diatrizoate Urografin Hypaque Renografin |
| Pronunciation | /daɪ.əˌtraɪˈzoʊ.ɪk ˈæs.ɪd/ |
| Identifiers | |
| CAS Number | 117-96-4 |
| 3D model (JSmol) | `5,1,1,2,3,2,3,2,2,1,2,2,2,3,3,3,3,2,2,2,2,2,2,2,2,2,3,3,3,3,2,3,3,3,2,2,2,2,2,2,2,2,2,2,2,3,3,3,3,2,2,2,2,2,2,2,3,3,3,2,2,3,3,2,2,2,3,2,3,2,2,2,2,3,3,3,2,2,2,2,3,3,3,3,2,2,2,2,2,2,2,2,2,2,2,2,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3` |
| Beilstein Reference | 3948186 |
| ChEBI | CHEBI:31523 |
| ChEMBL | CHEMBL1426 |
| ChemSpider | 13766 |
| DrugBank | DB00318 |
| ECHA InfoCard | 03fbd6f9-84bc-428a-8851-b2206b4329a5 |
| EC Number | 205-788-1 |
| Gmelin Reference | Gmelin Reference: **401432** |
| KEGG | C07366 |
| MeSH | D003977 |
| PubChem CID | 2202 |
| RTECS number | PA0700000 |
| UNII | 65XNX5VN8C |
| UN number | UN3082 |
| Properties | |
| Chemical formula | C11H9I3N2O4 |
| Molar mass | 635.886 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | Density: 2.09 g/cm³ |
| Solubility in water | freely soluble |
| log P | -0.5 |
| Vapor pressure | Negligible |
| Acidity (pKa) | 1.56 |
| Basicity (pKb) | 3.47 |
| Magnetic susceptibility (χ) | -62.5×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.684 |
| Viscosity | Viscosity: 3.7 cP |
| Dipole moment | 2.13 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 267 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -699.3 kJ/mol |
| Pharmacology | |
| ATC code | V08AA01 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. Causes skin irritation. May cause respiratory irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS07, GHS08 |
| Signal word | Warning |
| Hazard statements | H319: Causes serious eye irritation. |
| Precautionary statements | Keep out of reach of children. If medical advice is needed, have product container or label at hand. Avoid release to the environment. Dispose of contents/container in accordance with local/regional/national/international regulations. |
| NFPA 704 (fire diamond) | 2-1-0 |
| Flash point | > 238°C |
| Autoignition temperature | 275°C |
| Lethal dose or concentration | LD50 oral rat 12,000 mg/kg |
| LD50 (median dose) | LD50 8,200 mg/kg (rat, oral) |
| NIOSH | WN4900000 |
| PEL (Permissible) | Not established |
| REL (Recommended) | 50 mL |
| IDLH (Immediate danger) | IDLH: 50 mg/m³ |
| Related compounds | |
| Related compounds |
Iodipamide Iopanoic acid Iodixanol Iodinated contrast media |
